The Coming Age of Biosimilars MArket

Transcription

The Coming Age of Biosimilars MArket
The Coming Age of
Biosimilars - Regulatory
developments and
alliance strategies
intensify interest in a
developing market
Report Description
Biosimilars are attracting significant attention at present as companies from all sectors of the
biopharmaceutical market are investigating the opportunities they present.
Opinion is split as to the true potential of this market with some predicting it will grow to the
multi-billion dollar level within five years, while others point to the limited impact of
biosimilars in Europe to date to suggest that it will never be a major threat to branded
biologics.
To Get Complete Details Here @ http://www.bigmarketresearch.com/the-coming-age-ofbiosimilars-regulatory-developments-and-alliance-strategies-intensify-interest-in-adeveloping-market
Biosimilar pipelines are rapidly shifting away from the initial focus on the older, less complex,
biologics towards the higher earning monoclonal antibodies as well as developing, so called,
“biobetters” - similar biologics which offer improvements over the originator.
Report Description
“The Coming Age of Biosimilars - Regulatory developments and alliance strategies intensify
interest in a developing market” is a consultancy-style report focused on the many increasing
topics of biosimilars and their impending impact on the pharmaceutical industry. This report
will provide insights into the drivers & resistors, the developing pipeline, the regulatory
pathways, and the competitive landscape for biosimilars.
Enquire About Report@ http://www.bigmarketresearch.com/report-enquiry/132480
Please Note: This product is delivered as a zip file
Report Description
Scope
•
Introduction, overview and drivers and barriers to the biosimilars market
• Opportunity avenues and biosimilars defense strategies
• Competitive landscape assessment
Report Description
Key Reason To Purchase
• Understand the current state of the biosimilars market and the drivers & resistors which will
impact the area’s future growth.
• Identify & exploit effective biosimilar defense or launch strategies depending upon your
company’s stance on their impending arrival.
• Gain insights into the regulatory pathways currently in place, or in process, in the markets
you are targeting for biosimilar entry.
• Quickly get up to speed on the current global competitive biosimilar marketplace broken
down by company type and region.
Table Of Content
• Introduction to the biosimilar market
• The biosimilar pipeline
• The regulatory pathways
• Review of the competitive landscape
• Appendix
Table Of Content@ http://www.bigmarketresearch.com/the-coming-age-of-biosimilarsregulatory-developments-and-alliance-strategies-intensify-interest-in-a-developing-market
FOR MORE DETAILS
Visit us at :
http://www.bigmarketresearch.com/the-coming-age-ofbiosimilars-regulatory-developments-and-alliance-strategiesintensify-interest-in-a-developing-market
Stay With Us:
TELEPHONE: +1 (855) 711-1555
E-MAIL: sales@bigmarketresearch.com
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States

Similar documents

Biosimilars And Follow-On Biologics Market

Biosimilars And Follow-On Biologics Market Biosimilars is defined as a type of biological product that is similar to another drug, which has already been licensed (approved) by the US FDA or European Medicines Agency. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. These drugs are also coined as follow-on biologics and are mostly derived from biological sources such as bacterium and yeast. The constitution of the biosimilar drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biosimilars are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biosimilars can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. A good example for this is Pfizer acquisition of Hospira, to gain access to the latter’s attractive biosimilars portfolio. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biosimilar drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years.

More information